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Abstract
Purpose Pasireotide (SOM230), a novel multireceptor
ligand somatostatin analog (SSA), binds with high affinity
to four of the five somatostatin receptor subtypes (sst1–3, 5).
This study evaluated the safety, tolerability, pharmacoki-
netics, and pharmacodynamics profiles of pasireotide long-
acting release (LAR) formulation in patients with advanced
gastroenteropancreatic neuroendocrine tumor (GEP NET)
refractory to other SSAs.
Methods In this randomized, multicenter, open-label,
phase II study, patients with biopsy-proven primary or
metastatic GEP NET refractory to available SSAs were
randomly assigned 1:1:1 to receive pasireotide LAR by
deep intragluteal injection at a dose of 20, 40, or 60 mg
once every 28 days for 3 months.
Results Forty-two patients received pasireotide LAR.
Adverse events were reported by 34 (81 %) patients, with
the most frequently reported including diarrhea, fatigue,
abdominal pain, and nausea. Mean fasting glucose levels
were increased compared with baseline at all points
throughout the study. After the third injection of pasireo-
tide LAR, the median trough plasma concentrations on day
84 were 4.82, 12.0, and 19.7 ng/mL in the 20-, 40-, and
60-mg treatment groups, respectively. Drug accumulation
was limited for each dose based on the increase in trough
concentrations after the first to third injections (accumu-
lation ratios were approximately 1 from all dose levels).
Conclusions This study demonstrated that a new, once-
monthly, intramuscular LAR formulation of pasireotide
was well tolerated in patients with advanced GEP NET.
Steady state levels of plasma pasireotide were achieved
after three injections.
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Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP NET)
occur at an annual incidence of approximately 5 cases per
100,000 per year, and the estimated prevalence is[100,000
persons in the United States [1, 2]. Thus, these tumors are
significantly more prevalent than most other gastrointestinal
malignancies [2]. Patients with GEP NET have a 5-year
survival rate of 67.5 % across all tumor types. Most patients
present with distant metastases; the 5-year survival rate for
this population is 40.9 % [1]. GEP NET can secrete a wide
range of biologically active amines and peptides. The most
common is serotonin, which is responsible for the classic
symptoms of carcinoid syndrome (diarrhea, flushing, bron-
choconstriction, and right-sided valvular heart disease) [3].
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Somatostatin inhibits hormone release and cell growth
through binding to specific, cell surface, G-protein–coupled
receptors, of which five distinct subtypes (sst1–5) have been
characterized [4–6]. In pancreatic and gastrointestinal
endocrine tumors, sst2 expression predominates, although
multiple other subtypes have also been found [7]. The
limited clinical use of native somatostatin, because of its
very short half-life (\3 min) and the impact of rebound
hypersecretion, has necessitated the development of more
clinically useful analogs [6, 8, 9]. Development of the
somatostatin analog (SSA) octreotide (Sandostatin;
Novartis) was reported in 1982 [10] and was followed by
advancement of several other cyclic octapeptides, all of
which demonstrated increased resistance to peptidase
inactivation, substantially longer half-lives, and improved
pharmacologic efficacy [8]. Unlike natural somatostatin,
octreotide binds with high affinity only to the sst2 receptor
subtype and with lower binding affinity to the sst5 receptor,
and its activity does not cause rebound hormonal hyper-
secretion [7, 11].
Pasireotide (SOM230) is a novel, multireceptor ligand
SSA that binds with high affinity to four of the five
somatostatin receptor subtypes (sst1–3,5) [12]. The unique
binding profile of this SSA makes pasireotide a promising
new therapy for patients with advanced GEP NET,
including those refractory or resistant to octreotide and
lanreotide. In clinical trials, pasireotide subcutaneous (SC)
formulation has demonstrated efficacy and safety in
patients with acromegaly and Cushing’s disease [13–15].
In addition, SC injection of pasireotide effectively reduces
the symptoms of diarrhea and flushing in patients with
metastatic NET refractory or resistant to octreotide long-
acting repeatable (LAR) [16]. In this phase II study,
complete or partial symptom control was achieved in 27 %
of patients, and 57 % of patients had stable disease at
6 months. Adverse events (AEs), the most common of
which were gastrointestinal, were consistent with other
SSAs. Increases in blood glucose were also reported, but
these were generally well controlled and rarely led to
premature discontinuation of pasireotide. Although the SC
formulation of pasireotide required a twice-daily adminis-
tration schedule, a recent study [17] showed that continu-
ous 7-day infusion of pasireotide in healthy volunteers was
safe and well tolerated, presenting the opportunity for
development of an LAR formulation. This formulation is
administered intramuscularly (IM) monthly (once every
28 days). Early clinical data suggest a favorable safety
profile in combination with everolimus in patients with
advanced GEP NET [18].
The primary objective of the present study was to
evaluate the safety/tolerability and pharmacokinetic (PK)
profiles of monthly doses of pasireotide LAR (20, 40, and
60 mg/month) in patients with advanced GEP NET. The
secondary objectives of this study included an exploratory
pharmacodynamic (PD) assessment of the effect of pa-
sireotide LAR on bowel movement frequency—an impor-
tant efficacy endpoint of symptom control in patients with




This was a randomized, multicenter, open-label, phase I
study. After screening, eligible patients were randomly
assigned on a 1:1:1 basis to receive pasireotide LAR IM, by
deep intragluteal injection, at a dose of 20, 40, or 60 mg,
once every 28 days for 3 months.
Patients who had received recent therapy with an SSA
were required to complete a washout period before baseline
assessment. The washout period was 8 weeks for patients
who received octreotide LAR, lanreotide autogel, or any
other long-acting SSA; 4 weeks for those who received
lanreotide SR; and 2 days for those who received subcu-
taneous octreotide, subcutaneous pasireotide, or another
short-acting SSA. Further use of these drugs was not per-
mitted for the duration of the study. Before baseline, each
patient naive to subcutaneous pasireotide received a single
dose of subcutaneous pasireotide (300 lg) and was
observed for C5 days to ensure adequate pasireotide tol-
erability. Subcutaneous dosing was not required for
patients who had previously received subcutaneous pa-
sireotide outside this study.
After overnight fast, all patients underwent baseline
measurements of blood glucose, insulin, and glucagon,
followed by a standardized breakfast containing B100 g
carbohydrate. The first dose of pasireotide LAR was
administered at about 8:00 AM on the first day of dosing,
and subsequent doses were administered as close as pos-
sible to that time of day. Patients were assessed weekly for
the first 28 days of the study and every 2 weeks thereafter.
Blood samples for pharmacokinetic analyses and for
evaluation of blood glucose, insulin, and glucagon levels
were obtained at all assessments. Vital signs, blood
chemistry, complete blood count (CBC), and electrocar-
diogram (ECG) were evaluated throughout the study and at
study completion. Bowel movements were recorded
throughout the study using a daily diary. After the core
3-month treatment phase and at the discretion of the
investigator, an extension treatment phase of 3 months was
possible and could be followed by a second extension
treatment phase.
Patients were to be discontinued from the study if
they experienced any AE of grade C3 judged to be
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123
related to pasireotide, worsening of hormone-related
symptoms from carcinoid syndrome, or complications of
cancer requiring surgery or radiotherapy. Treatment was
also discontinued if the pasireotide LAR dose was
delayed for [7 days.
Patients
Adult male and female patients aged C18 years with
biopsy-proven primary or metastatic well-differentiated
GEP NET, refractory to available SSAs (octreotide or
lanreotide), were enrolled in this trial. All patients had
histopathologic confirmation of the diagnosis, elevated
levels of chromogranin A or serotonin (within the previous
6 months, if possible), and Karnofsky performance status
C60. Patients who received radiolabeled SSA therapy
within the past 6 months were excluded.
All patients provided written informed consent. The
protocol was approved by the institutional review board
or independent ethics committee at each participating
clinical center, and the study was conducted in
accordance with Good Clinical Practice and the Decla-
ration of Helsinki.
Assessments
Safety assessments consisted of recording all AEs. Blood
chemistry, CBC, urinalysis, vital signs, physical condition,
ECG, and body weight were checked regularly throughout
the study. In addition, an interim safety analysis was per-
formed when six patients had completed the first 6 weeks
of treatment. According to this prespecified analysis,
enrollment and treatment were to be stopped and a com-
prehensive review of all safety data was to be undertaken if
two or more patients in any dose cohort experienced seri-
ous AEs (SAEs; grade 3 or 4) judged related to pasireotide
LAR.
PK blood samples were collected at predose (0 h) and 2,
4, 6, 8, and 10 h after the first pasireotide LAR injection on
day 0 (the same day as injection); this was followed by PK
blood collection at 24 and 26 h on day 1 after the first
injection. Additional PK blood samples were collected at
Table 1 Patient demographics











Mean age, years (SD) 56.3 (12.6) 58.9 (12.7) 62.5 (9.6) 59.5 (11.6)
Male/female, n (%) 9 (75)/3 (25) 6 (43)/8 (57) 7 (44)/9 (56) 22 (52)/20 (48)
Race, n (%)
White 10 (83.3) 13 (92.9) 16 (100) 39 (92.9)
Black 1 (8.3) 0 0 1 (2.4)
Asian 1 (8.3) 0 0 1 (2.4)
Native American 0 1 (7.1) 0 1 (2.4)
Mean height, cm (SD) 176.4 (11.5) 169.5 (13.1) 168.9 (7.57) 171.2 (11.0)
Mean weight, kg (SD) 82.4 (15.9) 75.7 (18.7) 72.1 (12.3) 76.22 (15.9)
Mean BMI, kg/m2 (SD) 26.6 (5.3) 26.5 (6.7) 25.3 (4.0) 26.1 (5.3)
Median time since
diagnosis, days (range)
1,403 (94–3,504) 1,372.5 (222–8,691) 1,054.5 (133–3,321) 1,238 (94–8,691)
Median time since most
recent relapse, days
(range)
117 (34–1,066) 288.5 (76–1,973) 226 (65–1,184) 182.5 (34–1,973)
Previous antineoplastic
medications, n (%)
Yes 7 (58.3) 9 (64.3) 13 (81.3) 31 (68.9)
No 5 (41.7) 5 (35.7) 3 (18.8) 14 (31.1)
Previous antineoplastic
radiotherapy, n (%)
Yes 0 0 1 (6.3) 1 (2.2)
No 12 (100) 14 (100) 15 (93.8) 44 (97.8)
Previous antineoplastic
surgery, n (%)
Yes 12 (100) 13 (92.9) 15 (93.8) 43 (95.6)
No 0 1 (7.1) 1 (6.3) 2 (4.4)
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8:00 AM (a single collection) during visits on days 7, 14,
21, and 28 after the first LAR injection. For both second
and third LAR dosing, PK blood samples were collected
only at 8:00 AM on days 14 and 28 after injections.
Because of the sparse PK sampling, PK parameters of
interest included only pasireotide maximum concentration
(Cmax,day0–1,1st inj) from day 0 to day 1 after the first
injection, the trough-level concentration (Ctrough) on day 28
after the first, second, and third injections, and the accu-
mulation ratio (AR = Ctrough,d28,3rd inj/Ctrough,d28,1st inj).
PD response was measured by quantitative assessment
of daily bowel movements using the carcinoid disease
symptom diary.
Statistical analysis
The all-patients population consisted of all patients who
received at least one pasireotide injection (LAR, subcuta-
neous, or both), and the safety population consisted of all
patients who received at least one pasireotide LAR injec-
tion. The PK population consisted of all patients who
received at least one dose of pasireotide LAR and had
evaluable PK assessments. This set was used for summary
statistics of pasireotide concentration and PK parameters.
The PD population consisted of all patients who received at




In total, 45 patients were enrolled between June 2006 and
September 2007; of those, 42 were randomly assigned to
pasireotide LAR treatment (Table 1). Each of the three not
randomly assigned received a single SC injection of pa-
sireotide and was excluded from further participation in the
study because of an AE (n = 1), a protocol deviation
(n = 1), or an abnormal laboratory result (n = 1). All
remaining 42 randomly assigned patients received the first
dose of pasireotide LAR (20 mg, n = 12; 40 mg, n = 14;
60 mg, n = 16); 40 and 36 patients received the second
and third doses, respectively (Fig. 1). Of the six patients
who did not complete the study, three patients stopped
because of an AE, two died of disease progression, and one
withdrew consent. Patient demographics were comparable
between treatment groups (Table 1).
Safety and tolerability
Median duration of exposure was 84 days in all treatment
arms. In total, 34 of 42 patients (81.0 %) receiving
pasireotide LAR experienced at least one AE each. The
most frequently reported were diarrhea (n = 12; 28.6 %),
fatigue (n = 9; 21.4 %), abdominal pain (n = 8; 19.0 %),
and nausea (n = 7; 16.7 %) (Table 2). No relationship was
noted between incidence of AEs and dose of pasireotide.
Treatment-related AEs were reported in 24 patients (57 %)
at all dose levels. Diabetes mellitus (n = 5; 11.9 %) and
hyperglycemia (n = 4; 9.5 %) were the only treatment-
related AEs reported by more than two patients across all
treatment groups.
Fifteen patients reported grade 3/4 AEs (grade 3,
n = 12; grade 4, n = 3). The most frequently reported
grade 3/4 AEs (any dose) were diabetes mellitus and
flushing (n = 3 each) and abdominal pain, increased glu-
cose, hyperglycemia, hypokalemia, and liver metastases
(n = 2 each); all other grade 3/4 AEs were individual
reports of single events. Five patients discontinued treat-
ment early because of AEs (20 mg, n = 1; 40 mg, n = 3;
60 mg, n = 1). In addition to the two patients who died,
three patients discontinued treatment early because of
nonserious AEs (abdominal pain, hyperglycemia, and dia-
betes mellitus).
Five patients had SAEs—the two who died and the three
who had SAEs that did not lead to permanent study drug
discontinuation. One patient in the 40-mg group had a
small intestinal obstruction unrelated to study medication,
and one patient in the 60-mg group had two SAEs of




AE, n = 1
Protocol deviation, n = 1




















Death, n = 1
Discontinued
AE, n = 2
Death, n = 1
Discontinued
AE, n = 1
Withdrew 
consent, n = 1
Fig. 1 Patient disposition. AE Adverse event, LAR long-acting
release, SC subcutaneous
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medication. In addition, one patient in the 60-mg group had
diabetes mellitus related to study medication, complicated
by nonketotic hyperosmolar syndrome.
Two patients died during the study. One patient
receiving pasireotide LAR 20 mg died of cancer progres-
sion 25 days after receiving the first dose of pasireotide. A
second patient in the 40-mg group died 27 days after
receiving the first dose of pasireotide. The cause of death
was first reported as respiratory failure but was subse-
quently corrected by the investigator to cancer progression.
In addition, one patient who received only subcutaneous
pasireotide, but not the LAR formulation, died of cancer
progression complicated by spinal cord compression more
than 30 days after study discontinuation. No deaths were
considered by investigators to be related to study drug.
Laboratory values
Mean (median) fasting glucose levels were consistently
increased compared with baseline at all points throughout
the study. Baseline fasting blood glucose levels were 98.4
(96.3), 100.5 (95.8), and 98.2 (95.5) mg/dL, respectively,
in the 20-, 40-, and 60-mg groups and increased to 126.4
(121.6), 129.4 (123.4), and 130.1 (125.0) mg/dL 2 days
after the first dose of pasireotide. Levels remained elevated
during the study and were 129.3 (115.0), 165.3 (130.6), and
160.8 (150.0) mg/dL, respectively, at the end of the study.
Fasting insulin was slightly reduced in all treatment arms
compared with baseline, but post-baseline it remained
within the range of 4.2–7.4 mU/L in all treatment groups
for the duration of the study. Mean (median) baseline
fasting insulin level was higher in the 60-mg group at
baseline than in the 20- and 40-mg groups (12.5 [8.5] mU/
L vs 7.4 [6.7] mU/L and 7.2 [7.0] mU/L, respectively) but
normalized by day 2 and remained within a clinically
acceptable range for the remainder of the study. Overall, no
effect of treatment on fasting blood glucagon levels was
noted. At baseline, mean (median) glucagon levels
appeared slightly higher in the 60-mg group compared with
the 20- and 40-mg groups (82.3 [70.0] ng/L vs 72.8 [62.0]
ng/L and 70.0 [59.5] ng/L), but in all dose groups, gluca-
gon levels remained within the clinically accepted range
for the whole study. Mean glycosylated hemoglobin
(HbA1c) levels at baseline were 5.9, 6.0, and 5.9 % in the
20-, 40-, and 60-mg groups, respectively, and mean
increases from baseline to study conclusion were 0.6, 1.2,
and 1.4 %, respectively. Six patients developed detectable
urine glucose during treatment.
Two patients in the pasireotide LAR 60-mg group had
grade 3 hematologic abnormalities (decreased absolute
lymphocytes, n = 1; decreased absolute neutrophils,
n = 1); the only grade C3 laboratory abnormalities
occurring in two or more patients across all treatment arms
were total bilirubin (n = 2) and total triglycerides (n = 2).
No significant changes in ECG were observed, and five
patients had new or worsened gallbladder abnormalities at
the end of the study.
Pharmacokinetics
All 42 patients who received at least one dose of pasireo-
tide LAR were evaluable for PK analyses. Mean (±SD)
Table 2 Summary of adverse
events
Individual AEs occurring in
[10 % of patients across all
treatment arms are presented
Pasireotide long-acting release








Any adverse event 10 (83.3) 11 (78.6) 13 (81.3) 34 (81.0)
Diarrhea 4 (33.3) 4 (28.6) 4 (25.0) 12 (28.6)
Fatigue 3 (25.0) 3 (21.4) 3 (18.8) 9 (21.4)
Abdominal pain 3 (25.0) 4 (28.6) 1 (6.3) 8 (19.0)
Nausea 2 (16.7) 3 (21.4) 2 (12.5) 7 (16.7)
Diabetes mellitus 1 (8.3) 3 (21.4) 2 (12.5) 6 (14.3)
Dyspnea 2 (16.7) 3 (21.4) 1 (6.3) 6 (14.3)
Flushing 3 (25.0) 1 (7.1) 2 (12.5) 6 (14.3)
Headache 1 (8.3) 2 (14.3) 3 (18.8) 6 (14.3)
Anorexia 1 (8.3) 3 (21.4) 1 (6.3) 5 (11.9)
Asthenia 2 (16.7) 2 (14.3) 1 (6.3) 5 (11.9)
Treatment-related adverse event 6 (50) 10 (71.4) 8 (50) 24 (57.1)
Diabetes mellitus 1 (8.3) 3 (21.4) 1 (6.3) 5 (11.9)
Hyperglycemia 0 2 (14.3) 2 (12.5) 4 (9.5)
Serious adverse event 1 (8.3) 2 (14.3) 2 (12.5) 5 (11.9)
Discontinued because of adverse event 1 (8.3) 3 (21.4) 1 (6.3) 5 (11.9)
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pasireotide plasma concentration vs time profiles for the
three pasireotide LAR dose levels are shown in Fig. 2.
Steady state levels of pasireotide were achieved in all
treatment groups after the third LAR injection based on
trough concentrations collected on day 28 after each dose
(Fig. 2; Table 3). After the first injection of pasireotide
LAR, an initial burst was noted during the first 24 h;
median (mean ± SD) values of maximum plasma con-
centrations (Cmax,d0-1,1st inj) of pasireotide were 3.55
(4.50 ± 2.88), 5.39 (6.17 ± 4.08), and 6.09 (6.99 ± 4.09)
ng/mL in the 20-, 40-, and 60-mg treatment arms, respec-
tively (Table 3). Trough plasma concentrations of pasire-
otide on day 28 (Ctrough,d28,1st inj, median [mean ± SD])
after the first dose were 6.43 (6.31 ± 2.98), 8.56
(9.65 ± 5.89), and 16.5 (18.7 ± 9.3) ng/mL, respectively
(Table 3). Trough concentrations after the third injection
(Ctrough,day28,3rd inj, median [mean ± SD]) were 4.82
(5.6 ± 2.01), 12.0 (16.5 ± 10.2), and 19.7 (25.0 ± 20.5)
ng/mL for the 20-, 40-, and 60-mg dose levels. These
results suggested that PK exposures of pasireotide in
patients with carcinoid disease had large variability and
appeared to be slightly over dose proportional. However,
because of the limited sample size of patients and the large
interpatient variability in PK exposures, a definitive con-
clusion on dose proportionality could not be drawn. Med-
ian ARs were 0.998, 1.08, and 0.801, respectively, for the
20-, 40-, and 60-mg groups. In addition, concentration–
time profiles from individual patients (data not shown)
demonstrated that trough concentrations of pasireotide
reached steady state after three LAR injections in most of
the carcinoid patients.
Pharmacodynamics
The mean percentage change in average number of daily
bowel movements per week showed a decrease from
baseline at most time points for the 60-mg dose level,
whereas for the 40-mg dose level, fluctuation relative to
baseline levels was greater, and for the 20-mg dose group,
an increase was reported at all post-baseline time points
(Fig. 3). However, variability was high and sample size
was limited.
Discussion
SSAs such as octreotide represent the cornerstone of
symptomatic therapy for patients with carcinoid syndrome
from GEP NET; however, some patients develop resistance
to these drugs, possibly mediated through adaptive pro-
cesses at the cellular level [19–21]. These agents have high
affinity for the sst2 receptor and modest affinity for the sst5
receptor, and uncoupling or downregulation of the sst2
receptor may be a possible explanation for the decline in
efficacy occasionally seen with these drugs [19–22]. Pa-
sireotide is a multireceptor-targeted agent with high affinity
for four of the five known somatostatin receptor subtypes
(sst1–3,5) and higher binding affinity than octreotide at sst1,

























Pasireotide LAR 20 mg
Pasireotide LAR 40 mg
Pasireotide LAR 60 mg
Fig. 2 Plasma concentration versus time profiles of pasireotide in
patients with gastroenteropancreatic neuroendocrine tumor (GEP
NET) after three monthly injections. LAR Long-acting release
Table 3 Pharmacokinetic parameters of pasireotide following monthly injection with LAR 20, 40, or 60 mg in patients with GEP NET
Pasireotide long-acting release






Cmax,d0-1,1st inj (ng/mL) 3.55 (4.50 ± 2.88) 5.39 (6.17 ± 4.08) 6.09 (6.99 ± 4.09)
Ctrough,d28,1st inj (ng/mL) 6.43 (6.31 ± 2.98) 8.56 (9.65 ± 5.89) 16.5 (18.7 ± 9.3)
Ctrough,d28,2nd inj (ng/mL) 5.74 (6.14 ± 2.47) 9.68 (11.7 ± 7.7) 24.4 (27.6 ± 14.6)
Ctrough,d28,3rd inj (ng/mL) 4.82 (5.5 ± 2.01) 12.0 (16.5 ± 10.2) 19.7 (25.0 ± 20.5)
AR (Ctrough,d28,3rd inj/Ctrough,d28,1st inj) 0.998 (1.05 ± 0.57) 1.08 (1.68 ± 1.14) 0.801 (0.896 ± 0.432)
Data are expressed as median (mean ± SD)
AR Accumulation ratio, Cmax maximum concentration, Ctrough trough-level concentration
392 Cancer Chemother Pharmacol (2013) 72:387–395
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the somatostatin receptor subtypes [24], pasireotide may
offer symptom control for patients resistant to medical
treatment with octreotide or lanreotide.
Pasireotide LAR was well tolerated, with a safety profile
consistent with that in previous reports [15]. Most AEs were
mild or moderate and did not require pasireotide dose
adjustment, consistent with findings of a previous study of
subcutaneous pasireotide in patients with metastatic NET, in
whom nausea, abdominal pain, weight decrease, and
hyperglycemia were the most frequently reported (any
grade) AEs [16]. During treatment, an increase in mean
fasting blood glucose was noted, particularly in the 40- and
60-mg dose groups; however, insulin levels remained within
normal ranges for the duration of the study. It is unclear why
mean baseline insulin was elevated in the 60-mg dose group;
the standard deviation for this group suggests substantial
interpatient variability, as evidenced by the range of values
(1–42 mU/L) and the relatively small number of subjects
(n = 16). Glucagon levels also remained within the clini-
cally acceptable range for the duration of the study, and
HbA1c levels at the end of the 3-month study were similar in
all dose groups, suggesting adequate glucose control.
Although not apparent in the present study, previous reports
have suggested an association between long-acting formu-
lations of SSAs and reduction in fasting plasma insulin but no
significant effect on fasting plasma glucose [25]. Petersenn
and colleagues [17] noted an effect of pasireotide on fasting
blood glucose levels and suggested that it might have
resulted from an effect on hepatic glucose production caused
by the more pronounced suppression of insulin compared
with glucagon.
Pasireotide LAR injected IM once every 28 days led to
steady state pasireotide levels in all dose groups within
three injections. An initial burst was observed during the
first 24 h after the first LAR injection; the concentration
then decreased to the lowest level around day 7, followed
by an increase to the maximum concentration on day 21
after the first dose, reflecting the unique release profile of
the pasireotide LAR formulation. The PK release pattern
after the first dose in patients with GEP NET was similar to
that in healthy volunteers [17], but PK exposures in
patients with GEP NET were approximately twofold those
in healthy volunteers. This twofold PK exposure difference
between patients with GEP NET and healthy volunteers
was also observed for the pasireotide SC formulation [16].
The underlying reason for the twofold PK exposure dif-
ference between these populations remains unknown.
It should be noted that because of the limitations of this
study, including that it was not powered for efficacy end-
points, and that patient symptoms (including bowel move-
ment frequency and flushing) were not controlled at
baseline, no conclusions can be drawn regarding the control
of diarrhea and flushing. Therefore, a randomized phase III
study (Clinical Trial number NCT00690430) conducted to
compare the efficacy of pasireotide LAR 60 mg IM every
28 days vs octreotide LAR 40 mg IM every 28 days is
ongoing in patients with metastatic midgut NET whose
disease-related symptoms are inadequately controlled by
conventional doses of SSAs. It is anticipated that the results
of this ongoing phase III study may provide new insight into
the effects of pasireotide LAR on symptom control of
diarrhea and flushing in carcinoid syndrome [16].
A recent systematic review of SSAs in the treatment of
patients with GEP NET indicates that LAR formulations of
octreotide (Sandostatin LAR; Novartis) and lanreotide
(Somatuline SR/Autogel; Ipsen) provide symptom relief in
74.2 and 67.5 % of patients, and that 69.8 and 64.4 %,
respectively, experience tumor control [8]. The ability of
SSAs to control tumor growth was demonstrated in the
phase III PROMID study, in which octreotide LAR sig-
nificantly prolonged time to tumor progression compared
with placebo in patients with metastatic midgut NET (14.3
vs 6 months; hazard ratio 0.34; 95 % confidence interval
0.20–0.59; P = 0.000072) [26]. Overall, 66.7 % of
patients receiving octreotide and 37.2 % of those receiving
placebo had stable disease after 6 months of therapy [26].
In the phase III RADIANT-2 study, the addition of ever-
olimus to octreotide suggested an extension of progression-
free survival [27].
A number of elements regarding the design of this study
are worth additional comment. Recently released consen-
sus guidelines establish key unmet needs, develop appro-
priate study endpoints, and standardize clinical trial
inclusion criteria for research on NET [28]. Relevant to the
present study, these guidelines advocate avoidance of a
washout period before study initiation as ethically unac-
ceptable and unnecessary provided study durations are
sufficiently long to rule out carryover effects from previous
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Fig. 3 Percentage change from baseline in mean weekly bowel
movements (data are mean ± SD)
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publication of these guidelines; hence, we could not con-
sider this recommendation during study design. However,
with the potential for saturation of pasireotide elimination
pathways at higher doses, it is equally possible that the
concurrent presence of any agents using the same elimi-
nation pathways (e.g., carryover of a previously used long-
acting SSA) could result in artificially increased pasireotide
plasma concentrations during the early stages of the study.
In conclusion, a new once-monthly IM LAR formulation
of pasireotide was well tolerated in patients with GEP NET
refractory to available SSAs, with a toxicity profile con-
sistent with that in previous reports. Steady state levels of
plasma pasireotide were achieved within three injections.
These observations support the continued evaluation of
pasireotide LAR in patients with GEP NET. An ongoing
study is being conducted to determine the maximum tol-
erated dose above 60 mg, and a comparative randomized
phase III study is expected to provide further data regard-
ing the clinical effectiveness of this treatment. Moreover,
the tolerability profile of pasireotide supports the potential
use of this new agent in combination regimens.
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